Notice of Proposed Sale · 144
Veradermics, Incorporated
MANENYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- VERADERMICS INC
- Issuer CIK
- 0001827635
- SEC file number
- 001-43097
- Phone
- 228-372-3376
- Person for whose account securities are to be sold
- Reid Alexander Waldman
- Relationships to issuer
- CEO
- Street
- 470 James Street
- City
- New Haven
- State / country code
- CT
- Postal code
- 06513
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 135,000 | 15,022,800 | 41,780,136 | 08/17/2026 | NYSE | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue
- Street (continued)
- 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/17/2026 | Stock Option | Issuer | 3,452 | N | 08/17/2026 | Cash |
| Common | 03/24/2020 | Founder Shares | Issuer | 131,548 | N | 03/24/2020 | NA |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Reid Alexander Waldman.
Company context
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options: